LRMR — Larimar Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1374690 ·
Last close
$3.54
Market Cap
$367.75M
52W High
$5.35
52W Low
$3.04
ADV30
1,879,436
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -31,117,000 | -29,613,000 | 208,511,000 | 177,913,000 | 50,478,000 |
| Dec 2025 | 0 | — | -64,018,000 | -62,498,000 | 145,842,000 | 85,412,000 | 67,757,000 |
| Sep 2025 | 0 | — | -49,499,000 | -47,712,000 | 187,350,000 | 90,140,000 | 48,312,000 |
| Jun 2025 | 0 | — | -27,792,000 | -26,182,000 | 149,988,000 | 20,587,000 | 30,134,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-131,275,000
Investing CF
$114,861,000
Financing CF
$173,201,000
CapEx
$-270,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.06
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-464,444,000
Inventory
—
Receivables
$791,000
ST Investments
$22,472,000
EBIT TTM
$-172,426,000
Pretax Income TTM
$-166,005,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -172,497,000 | -165,673,000 | 145,842,000 | 67,757,000 | — | -113,201,000 |
| Dec 2024 | 0 | -90,890,000 | -80,604,000 | 200,225,000 | 28,413,000 | — | -70,760,000 |
| Dec 2023 | 0 | -41,758,000 | -36,949,000 | 95,935,000 | 14,215,000 | — | -33,459,000 |
| Dec 2022 | 0 | -36,526,000 | -35,355,000 | 126,405,000 | 15,502,000 | — | -27,569,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.23
Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $3.54 · call volume: 67 · put volume: 55Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENTA | ENANTA PHARMACEUTICALS INC | $367.55M | $12.64 | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $368.00M | $7.23 | — |
| VSTM | Verastem, Inc. | $366.43M | $4.17 | — |
| CYDY | CytoDyn Inc. | $373.94M | $0.27 | — |
| FBRX | Forte Biosciences, Inc. | $360.22M | $17.59 | — |
News headlines (Yahoo Finance, 1h cache)
Exploring 3 High Growth Tech Stocks in US Market
2026-06-15 11:39 · Yahoo
Exploring US High Growth Tech Stocks This May 2026
2026-05-15 11:38 · Yahoo
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
2026-05-14 11:00 · Yahoo
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
2026-04-30 20:05 · Yahoo
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13
2026-03-27 07:30 · Yahoo
Larimar: Q4 Earnings Snapshot
2026-03-19 11:22 · Yahoo
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-19 11:00 · Yahoo
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
2026-03-06 15:26 · Yahoo
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
2026-03-04 21:05 · Yahoo
Larimar Therapeutics price target raised to $12 from $11 at Wedbush
2026-03-04 13:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.